Q4 EPS Forecast for Merit Medical Systems Lifted by Analyst

Key Points

• Zacks Research has raised its Q4 2025 earnings per share estimate for Merit Medical Systems to $0.82, up from a previous forecast of $0.75.
• Merit Medical Systems' latest quarterly earnings report exceeded expectations, with earnings per share of $1.01 and revenue of $382.46 million, marking a 13.2% increase year-over-year.
• The stock has received a consensus rating of "Moderate Buy" from analysts, with an average price target of $107.00 after various price adjustments by investment firms.

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Equities researchers at Zacks Research lifted their Q4 2025 EPS estimates for Merit Medical Systems in a research report issued on Wednesday, August 20th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $0.82 per share for the quarter, up from their prior forecast of $0.75. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems' Q1 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.88 EPS, Q4 2026 earnings at $0.96 EPS and Q1 2027 earnings at $0.84 EPS.

A number of other equities research analysts have also recently weighed in on the stock. Barrington Research reissued an "outperform" rating and issued a $103.00 price target on shares of Merit Medical Systems in a research report on Thursday, July 31st. Needham & Company LLC reaffirmed a "buy" rating and issued a $108.00 target price on shares of Merit Medical Systems in a report on Friday, July 18th. Piper Sandler reduced their target price on shares of Merit Medical Systems from $110.00 to $105.00 and set an "overweight" rating for the company in a report on Thursday, July 31st. Wells Fargo & Company reduced their target price on shares of Merit Medical Systems from $108.00 to $100.00 and set an "overweight" rating for the company in a report on Thursday, July 31st. Finally, Canaccord Genuity Group set a $112.00 target price on shares of Merit Medical Systems and gave the company a "buy" rating in a report on Wednesday, May 21st. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $107.00.

Merit Medical Systems Stock Performance

MMSI traded up $0.49 on Monday, reaching $90.54. The company had a trading volume of 366,258 shares, compared to its average volume of 478,851. Merit Medical Systems has a 1 year low of $81.04 and a 1 year high of $111.45. The stock has a market capitalization of $5.36 billion, a PE ratio of 45.96, a P/E/G ratio of 2.92 and a beta of 0.66. The company has a quick ratio of 2.66, a current ratio of 4.09 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average price of $88.41 and a 200-day moving average price of $94.46.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported $1.01 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.16. Merit Medical Systems had a net margin of 8.31% and a return on equity of 15.07%. The firm had revenue of $382.46 million during the quarter, compared to analysts' expectations of $372.47 million. During the same period in the previous year, the company earned $0.92 earnings per share. Merit Medical Systems's quarterly revenue was up 13.2% compared to the same quarter last year.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 400 shares of the company's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $95.61, for a total transaction of $38,244.00. Following the transaction, the chief executive officer directly owned 1,045,628 shares in the company, valued at approximately $99,972,493.08. This represents a 0.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lynne N. Ward sold 3,000 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $88.56, for a total transaction of $265,680.00. Following the transaction, the director owned 12,809 shares in the company, valued at $1,134,365.04. The trade was a 18.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,514 shares of company stock valued at $2,264,465. 3.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its position in Merit Medical Systems by 1.1% during the second quarter. State Street Corp now owns 2,218,432 shares of the medical instruments supplier's stock worth $207,379,000 after buying an additional 24,569 shares during the period. Invesco Ltd. grew its position in shares of Merit Medical Systems by 16.4% in the first quarter. Invesco Ltd. now owns 1,787,289 shares of the medical instruments supplier's stock valued at $188,934,000 after purchasing an additional 251,821 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its position in shares of Merit Medical Systems by 8.2% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,766,711 shares of the medical instruments supplier's stock valued at $186,759,000 after purchasing an additional 133,465 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Merit Medical Systems by 2.8% in the second quarter. Geode Capital Management LLC now owns 1,437,397 shares of the medical instruments supplier's stock valued at $134,384,000 after purchasing an additional 39,620 shares during the last quarter. Finally, Maverick Capital Ltd. grew its position in shares of Merit Medical Systems by 8.4% in the second quarter. Maverick Capital Ltd. now owns 1,379,408 shares of the medical instruments supplier's stock valued at $128,947,000 after purchasing an additional 106,897 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.